Solid Biosciences Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SLDB Nasdaq 2834 www.solidbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Solid Biosciences Inc.

Solid Biosciences to Participate at Upcoming Investor Conferences - Sep 2nd, 2026 6:00 am
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 2:08 pm
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base? - Jul 1st, 2026 9:28 pm
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says - Jun 18th, 2026 9:04 am
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors - Jun 8th, 2026 1:00 am
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics - Jun 2nd, 2026 5:00 am
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 1st, 2026 2:05 pm
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - May 20th, 2026 6:36 am
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - May 12th, 2026 2:08 pm
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy - May 7th, 2026 6:00 am
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy - Apr 30th, 2026 6:00 am
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy - Apr 28th, 2026 6:00 am
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Mar 19th, 2026 2:12 pm
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Mar 12th, 2026 11:10 am
Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks - Mar 11th, 2026 3:55 pm
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Mar 11th, 2026 11:01 am
Solid Biosciences Announces Oversubscribed $240 Million Private Placement - Mar 6th, 2026 6:31 am